Table 4.

Prediction of absorption changes in oral antineoplastic drugs for which the food effects are unknown

Prediction	Generic name	Usage	logP	lnFaSSGF	lnFaSSIF	lnFeSSIF
absorption increase (logP ≥4.34)	toremifene citrate	–	6.73	− 2.23	−4.34	−0.73
	tamoxifen citrate	–	6.64	−2.11	−4.20	−0.58
	tretinoin	postprandial	6.07	−6.91	−3.44	−1.13
	mitotane	–	6.06	−6.91	−4.42	−1.06
	mepitiostane	–	6.01	−7.83	−4.51	−2.56
	tamibarotene	postprandial	5.80	−5.81	−3.06	−1.13
	cytarabine ocfosphate hydrate	postprandial	4.56	−4.02	−5.81	−5.81
no prediction	medroxyprogesterone acetate	–	3.94	−5.30	−4.27	−2.59
	estramustine phosphate sodium hydrate	–	3.92	−3.30	−1.20	−1.56
	flutamide	postprandial	2.90	−2.69	− 2.15	−1.72
	anastrozole	–	2.67	−2.90	−3.54	−1.48
absorption invariant (logP < 1.59)	cyclophosphamide hydrate	–	0.77	2.47	1.96	2.84
	etoposide	–	0.76	−2.00	−1.80	−1.51
	sobuzoxane	–	0.46	−0.11	−3.04	−1.94
	tegafur	–	−0.12	1.35	1.49	2.28
	tegafur/gimeracil/oteracil potassium	postprandial	−0.12	1.35	1.49	2.28
	melphalan	–	−0.34	2.27	1.29	0.77
	mercaptopurine hydrate	–	−0.52	0.91	−1.14	−0.46
	fluorouracil	–	−0.81	1.49	1.66	2.67
	busulfan	–	−0.81	3.35	7.89	5.01
	doxifluridine	–	−1.08	2.50	3.57	3.36
	methotrexate	–	−1.11	3.02	1.06	−1.86
	hydroxycarbamide	–	−1.66	3.90	3.74	3.12
	ubenimex	–	−1.67	3.33	2.26	1.72